

CBD AIF

Medical Sector Summary

San Diego

January 9th, 2008

Kim C. Bush

Speed of Clearance Process

- **In general, not applicable to medical sector**
 - Majority of partnered medical product contract development work is either unclassified and / or done off-site.
 - Product, therapy and equipment training done mostly in non-restricted areas
 - Govt takes responsibility for secure storage, testing and protection of finished product (NPS)
- **Key Challenge** – access of non-US nationals (R&D & MDs) to military bases conducting research and / or clinical work
 - DOD usually accommodates off-site meetings
 - Prime contractor or pre-authorized contract integrators can usually accommodate subcontractor meeting needs

Demo needs at CBRN Conference

- Most respondents – “not applicable” or “awaiting agenda”
- Therapeutics usually covered through technical presentations and posters
- Medical sector currently focused mostly on diagnostics & new therapeutic product development (*vaccines, antibiotics, therapeutic proteins, antivirals, & Mabs*)
 - Primary targets - BARDA identified *Material Threat Determinations, CDC category A, B & C pathogens, TMTI pathogen concerns*
 - Pathogen / risk focus – Small pox, anthrax, hemorrhagic fevers, botulism, tularemia, plague, antibiotics, radiation and anti-nerve gas therapeutics

Joint Chemical Biological Decontamination & Protection Conference & Exhibition

Baxter

- Most respondents – “not applicable”
- Additional info on areas of interest from Medical perspective
 - Status of current DoD clinical research projects
 - Partnering Opportunities
 - New Pathogens of interest